Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Receivables (2019 - 2025)

Historic Receivables for Seres Therapeutics (MCRB) over the last 5 years, with Q3 2025 value amounting to $404000.0.

  • Seres Therapeutics' Receivables changed N/A to $404000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $404000.0, marking a year-over-year change of. This contributed to the annual value of $2.7 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Seres Therapeutics reported Receivables of $404000.0 as of Q3 2025.
  • Over the past 5 years, Seres Therapeutics' Receivables peaked at $9.0 million during Q1 2025, and registered a low of $404000.0 during Q3 2025.
  • For the 3-year period, Seres Therapeutics' Receivables averaged around $2.9 million, with its median value being $1.9 million (2021).
  • Within the past 5 years, the most significant YoY rise in Seres Therapeutics' Receivables was 2495.2% (2021), while the steepest drop was 6315.94% (2021).
  • Over the past 3 years, Seres Therapeutics' Receivables (Quarter) stood at $1.2 million in 2021, then skyrocketed by 114.64% to $2.7 million in 2024, then tumbled by 84.94% to $404000.0 in 2025.
  • Its Receivables was $404000.0 in Q3 2025, compared to $9.0 million in Q1 2025 and $2.7 million in Q4 2024.